Preparations for the Start of the CTX-439 Clinical Trial
First written in FY2024-Q3. 2 of 5 entries say "Restated". Latest entry: 2026-10-15.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「For CTX-439, a CDK12 inhibitor currently in the preclinical stage, we have completed the safety studies and manufacture of the investigational drug substance needed to initiate clinical trials, and are preparing for the next phase using in-house research and grants from AMED and other sources.」
CTX-439 has completed its safety studies and manufacture of the investigational drug substance, and preparation for the next development stage continues with the use of grants from AMED and other sources. - FY2024RestatedAnnual report
「As of the filing date, we had completed the safety studies and manufacture of the investigational drug substance needed to initiate clinical trials, and were preparing for the next phase.」
CTX-439 remains in the preparation stage for initiating clinical trials following completion of the safety studies and manufacture of the investigational drug substance. - FY2024-Q3First statedAnnual report
「For CTX-439, a CDK12 inhibitor currently in the preclinical stage, we have completed the safety studies and manufacture of the investigational drug substance needed to initiate clinical trials, and are currently preparing for the next phase.」
The safety studies and manufacture of the investigational drug substance have been completed, and preparation for the next development stage is under way.